Yarrow Bioscience, Inc. (VYNE) research
Yarrow Bioscience, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $28.56
- As of
Yarrow Bioscience, Inc. (VYNE): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-14.
As of . Source: SEC EDGAR filings for VYNE. Method and limitations.
Share the VYNE intelligence card
See the full VYNE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VYNE on one page. Preview it with sample data, then open it live with a free account.
Preview the VYNE dossierActive signals for VYNE
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1435% to VYNE (2026Q2)
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in VYNE
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +94% to VYNE (2026Q1)
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 38.5% - EPS $-0.11292 vs $-0.1836 estimate
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 42.9% - EPS $-0.13 vs $-0.2278 estimate
FREE, NO ACCOUNT
Every signal on VYNE, as it fires
You are seeing 5 of 8 signals recorded on VYNE since 2026-05-31.
The five above landed across 4 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in VYNE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 92941V308 · 2026Q2 | $305K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 92941V308 · 2026Q2 | $286K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 92941V308 · 2026Q2 | $15K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, VYNE
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
VYNE mentioned in Kresmion daily briefs
VYNE against its peers
VYNE's operating margin of -5219.1% ranks in the 15th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | VYNE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 570000 USD | 2.6M USD | 23 | 10 |
| Operating margin | -5219.1% | -363.5% | 15 | 9 |
| Net margin | -4646.1% | -343.0% | 15 | 9 |
| Return on equity | -95.4% | -111.7% | 57 | 19 |
Peers (22): AKTX, ESLA, MRKR, DYAI, ATOS, SNSE, NEUP, KPTI, TVRD, ACTU, INTI, JSPR, CLRB, LPCN, PTN, NCEL, LSTA, KTTA, TCRX, BCDA, CYCN, NXTC. Left out: PBM (period gap), FNCHQ (period gap), RADX (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (VYNE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more VYNE signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to VYNEand get the insider, 13F, options, and confluence read in one view.